CN112043788A - A topical pharmaceutical composition for treating gout and preparation method thereof - Google Patents
A topical pharmaceutical composition for treating gout and preparation method thereof Download PDFInfo
- Publication number
- CN112043788A CN112043788A CN202011084696.2A CN202011084696A CN112043788A CN 112043788 A CN112043788 A CN 112043788A CN 202011084696 A CN202011084696 A CN 202011084696A CN 112043788 A CN112043788 A CN 112043788A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- treating gout
- mixture
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an external pharmaceutical composition for treating gout and a preparation method thereof, relating to the technical field of external pharmaceutical compositions, wherein the external pharmaceutical composition for treating gout comprises the following raw material components: lily, Chinese pulsatilla root, divaricate saposhnikovia root, dahurian angelica root, Mongolian snakegourd root, menthol, borneol, azone, 1, 3-butanediol, 1, 2-pentanediol, carbomer, diethanolamine, dipotassium glycyrrhizinate, methyl paraben, glycerol and water. The external medicine composition for treating gout provided by the invention adopts lily, Chinese pulsatilla root, divaricate saposhnikovia root, dahurian angelica root, mongolian snakegourd root, menthol and borneol as the raw material components of the traditional Chinese medicine, is green and natural, does not contain hormone, can be used for a long time, and can efficiently relieve pain by the effective components; the menthol, the borneol, the azone, the 1, 3-butanediol and the 1, 2-pentanediol are used as the raw material components of the transdermal agent, so that the active ingredients of the traditional Chinese medicine can be quickly transdermally penetrated, the drug effect is exerted, and the effect of quickly curing and relieving pain is achieved.
Description
Technical Field
The invention relates to the technical field of external pharmaceutical compositions, in particular to an external pharmaceutical composition for treating gout and a preparation method thereof.
Background
Gout is a common and complex type of arthritis that can develop in all ages. Patients with gout often have sudden joint pain at night, the joint is in urgent attack, severe pain, edema, red swelling and inflammation appear at the joint, and the pain is slowly relieved until the pain disappears for days or weeks.
At present, no external medicine and health care product batch taking gout as a main treatment function exists in the market. Only other analgesic topical products: the western medicine analgesic external product is mainly a non-steroidal anti-inflammatory product, mainly has anti-inflammatory effect, has a certain analgesic effect, but has an undesirable analgesic effect on gout and cannot be used for a long time. The traditional Chinese medicine pain-relieving external product mainly takes rheumatic bone pain as main material, and the pain-relieving effect on gout can not meet the clinical requirement.
The pain in acute stage of gout is severe, rapid pain relief is needed, the transdermal speed of the product is high, and the existing ointment product basically takes azone as a main transdermal agent and has poor transdermal auxiliary effect with traditional Chinese medicine macromolecules.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides an external pharmaceutical composition for treating gout and a preparation method thereof.
The external medicine composition for treating gout comprises the following raw material components: lily, Chinese pulsatilla root, divaricate saposhnikovia root, dahurian angelica root, Mongolian snakegourd root, menthol, borneol, azone, 1, 3-butanediol, 1, 2-pentanediol, carbomer, diethanolamine, dipotassium glycyrrhizinate, methyl paraben, glycerol and water.
Preferably, the external pharmaceutical composition for treating gout comprises the following raw material components in parts by weight: 5-40 parts of lily, 10-40 parts of Chinese pulsatilla root, 5-30 parts of divaricate saposhnikovia root, 5-20 parts of angelica dahurica, 10-30 parts of trichosanthes root, 3-10 parts of menthol, 4-20 parts of borneol, 0.5-2 parts of azone, 1-5 parts of 1, 3-butanediol, 1, 2-pentanediol, 0.8-1.2 parts of carbomer, 0.02-0.04 part of diethanolamine, 0.08-0.12 part of dipotassium glycyrrhizinate, 0.5-2 parts of methylparaben, 2.5-3.5 parts of glycerol and 50-80 parts of water.
Further preferably, the external pharmaceutical composition for treating gout comprises the following raw materials in parts by weight: 35 parts of lily, 25 parts of Chinese pulsatilla root, 10 parts of divaricate saposhnikovia root, 10 parts of angelica dahurica, 13 parts of trichosanthes root, 3 parts of menthol, 4 parts of borneol, 1 part of azone, 4 parts of 1, 3-butanediol, 2 parts of 1, 2-pentanediol, 1 part of carbomer, 0.03 part of diethanolamine, 0.1 part of dipotassium glycyrrhizinate, 1.25 parts of methyl hydroxybenzoate, 3 parts of glycerol and 70 parts of water.
In the raw material components, lily, Chinese pulsatilla root, divaricate saposhnikovia root, dahurian angelica root, Mongolian snakegourd root, menthol and borneol are used as traditional Chinese medicine components to provide effective components for treating gout; menthol, borneol, azone, 1, 3-butanediol and 1, 2-pentanediol are components of the transdermal agent, wherein the menthol and the borneol in the traditional Chinese medicine components have the transdermal effect at the same time; carbomer, diethanol amine, dipotassium glycyrrhizinate, methyl hydroxybenzoate, glycerol and water are taken as auxiliary components.
The preparation method of the external pharmaceutical composition for treating gout comprises the following steps:
s1, mixing lily and Chinese pulsatilla root to obtain a mixture A, and extracting the mixture A with water to obtain an extracting solution A for later use;
s2, preparing a mixture B from the divaricate saposhnikovia root, the dahurian angelica root and the Mongolian snakegourd root, and extracting the mixture B with water to obtain an extracting solution B for later use;
s3, mixing menthol and borneol, and grinding the mixture into semi-liquid state to obtain a mixture C for later use;
s4, mixing the extracting solution A and the extracting solution B, and concentrating to obtain a concentrated solution;
s5, adding the mixture C, glycerol, half of 1, 3-butanediol, half of 1, 2-pentanediol, glycerol and the balance of water into the concentrated solution, uniformly mixing, heating, emulsifying, cooling, adding azone, half of 1, 3-butanediol, half of 1, 2-pentanediol, dipotassium glycyrrhizinate and methyl paraben, uniformly mixing, adding triethanolamine to adjust the pH value, and preparing a mixture D;
s6, filling or pasting the mixture D to obtain the external medicine composition for treating gout;
in step S1, the weight ratio of the mixture a to water is 1: 6; in step S2, the weight ratio of the mixture B to water is 1: 5.
preferably, in step S1, the extraction is performed at 100 ℃ for 5 hours each time for 2 times.
Preferably, in step S2, the extraction is performed 2 times at 100 ℃ for 2 hours each time.
Preferably, in step S4, the concentration is performed to a density of 1.1g/cm3。
Preferably, in step S5, the PH is adjusted to 6.6-7.
The invention has the beneficial effects that:
(1) the external medicine composition for treating gout provided by the invention adopts lily, Chinese pulsatilla root, divaricate saposhnikovia root, dahurian angelica root, mongolian snakegourd root, menthol and borneol as the raw material components of the traditional Chinese medicine, is green and natural, does not contain hormone, can be used for a long time, and can efficiently relieve pain by the effective components; the menthol, the borneol, the azone, the 1, 3-butanediol and the 1, 2-pentanediol are used as the raw material components of the transdermal agent, so that the active ingredients of the traditional Chinese medicine can be quickly transdermally penetrated, the drug effect is exerted, and the effect of quickly curing and relieving pain is achieved.
(2) The external medicine composition for treating gout provided by the invention meets the prescription requirements of medicines and health care products specified by the state, fills the gap of external medicines for treating gout, and has great commercial value.
(3) The preparation method of the external pharmaceutical composition for treating gout provided by the invention is simple to operate, stable in process, easily available in raw materials and strong in operability, active ingredients of the raw materials can be retained to the maximum extent, and the prepared external pharmaceutical composition for treating gout is rapidly released, so that the effect is remarkable.
Detailed Description
Hereinafter, embodiments of the present invention will be described in detail. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
It is to be noted that, unless otherwise specified, technical or scientific terms used herein shall have the ordinary meaning as understood by those skilled in the art to which the invention pertains.
Example 1
The external pharmaceutical composition for treating gout comprises the following raw materials in parts by weight: 35 parts of lily, 25 parts of Chinese pulsatilla root, 10 parts of divaricate saposhnikovia root, 10 parts of angelica dahurica, 13 parts of trichosanthes root, 3 parts of menthol, 4 parts of borneol, 1 part of azone, 4 parts of 1, 3-butanediol, 2 parts of 1, 2-pentanediol, 1 part of carbomer, 0.03 part of diethanolamine, 0.1 part of dipotassium glycyrrhizinate, 1.25 parts of methyl hydroxybenzoate, 3 parts of glycerol and 70 parts of water.
The preparation method of the external pharmaceutical composition for treating gout comprises the following steps:
s1, mixing lily and Chinese pulsatilla root to obtain a mixture A, and extracting the mixture A with water to obtain an extracting solution A for later use;
s2, preparing a mixture B from the divaricate saposhnikovia root, the dahurian angelica root and the Mongolian snakegourd root, and extracting the mixture B with water to obtain an extracting solution B for later use;
s3, mixing menthol and borneol, and grinding the mixture into semi-liquid state to obtain a mixture C for later use;
s4, mixing the extracting solution A and the extracting solution B, and concentrating to obtain a concentrated solution;
s5, adding the mixture C, glycerol, half of 1, 3-butanediol, half of 1, 2-pentanediol, glycerol and the balance of water into the concentrated solution, uniformly mixing, heating, emulsifying, cooling, adding azone, half of 1, 3-butanediol, half of 1, 2-pentanediol, dipotassium glycyrrhizinate and methyl paraben, uniformly mixing, adding triethanolamine to adjust the pH value, and preparing a mixture D;
s6, filling or pasting the mixture D to obtain the external medicine composition for treating gout;
in step S1, the weight ratio of the mixture a to water is 1: 6; in step S2, the weight ratio of the mixture B to water is 1: 5.
in step S1, the extraction is performed at 100 ℃ for 2 times, each time for 5 hours.
In step S2, the extraction is performed 2 times at 100 ℃ for 2 hours each time.
In step S4, the concentration is carried out until the density is 1.1g/cm3。
In step S5, the PH is adjusted to 7.
Test example 1
The raw material components of the external pharmaceutical composition for treating gout are screened according to the mixture ratio
Firstly, the sources of the raw material components are shown in Table 1
TABLE 1
Second, test contents
1.1 Positive: diclofenac diethylamine emulsion agent, specification: 20 grams/tube, 1 tube/box, lot number: VJ4M, produced by GSK Consumer Healthcare Schweiz AG.
1.2 animal, feed and rearing Environment
Animals: ICR mice, SPF grade, male, body weight 19-20g, liening biotechnology, ltd, production license number: SCXK (jeao) 2015 + 0001, quality certification number: 211002300049396, respectively;
feed: rat and mouse maintenance feed, batch number 19073211, Beijing Ke's Australian cooperative feed Co., Ltd., license number: kyo feeding certificate (2014) 06054;
a breeding environment: barrier environment animal observation room, temperature: 21-25 ℃, relative humidity: 40-70%, the license number used by experimental animals: SYXK (Ji) 2015-0009.
1.3 Main instruments and reagents
Counter, model: i30, Shenzhen, Hai Tian Di science and technology Limited; electronic balance, model: DT100, well-known double jie test instrument factory; glacial acetic acid (analytical grade), batch number: 20181025, Beijing chemical plant; weiting depilatory cream, batch number: 2022050401x, product of Lijie time chemical (China) Co.
1.4 test methods
30 mice were obtained by the writhing method, and the abdomen was depilated in the range of 2.6cm x 3 cm. Mice were randomly divided into 3 groups of 10 mice each, namely a blank control group, a positive control group and a test substance group. After 24 hours of depilation, 0.6% acetic acid was intraperitoneally injected at 0.1ml/10g BW into each mouse in the blank control group, and the number of writhing of each mouse within 15min after administration of the analgesic agent was recorded by a counter; uniformly coating a test object on parchment paper according to the dose of 0.5 g/mouse, then pasting the parchment paper on the abdomen of a tested mouse, and fixing the test object by using a non-irritant adhesive plaster; treating the positive substance according to the same dosage and method of the test substance; after 30min, the covering is respectively uncovered, acetic acid is injected according to the method of a blank control group, and the times of writhing of the mice are recorded.
1.5 data statistics
Data analysis was performed using SPSS statistical software. The two sets of mean comparisons were performed using a t-test in sets.
(1) Screening of Chinese medicine raw material components in proportion
TABLE 2
(2) Proportioning screening of raw material components of transdermal agent
TABLE 3
Test example 2
Pain-relieving effect test of the pharmaceutical composition for external use for treating gout prepared in example 1
Test site: jilin leads to ventilation in east Chang district.
The test method comprises the following steps: in 2019, 120 patients with local gout acute attack are randomly selected, the patients are divided into three groups, the external pharmaceutical composition for treating gout, the rheumatic ostealgia ointment and the non-steroidal anti-inflammatory cream which are prepared in the embodiment 1 are respectively externally applied and smeared once every 4 hours and 3 times, and the pain relieving effect is tested for 12 hours.
TABLE 4
| Example 1 | Rheumatism ostealgia plaster | Non-steroidal anti-inflammatory cream | |
| 12-hour pain relief ratio (%) | 77.5％ | 35.0％ | 57.5％ |
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention, and they should be construed as being included in the following claims and description.
Claims (8)
1. A topical pharmaceutical composition for treating gout, comprising: the external medicine composition for treating gout comprises the following raw material components: lily, Chinese pulsatilla root, divaricate saposhnikovia root, dahurian angelica root, Mongolian snakegourd root, menthol, borneol, azone, 1, 3-butanediol, 1, 2-pentanediol, carbomer, diethanolamine, dipotassium glycyrrhizinate, methyl paraben, glycerol and water.
2. The topical pharmaceutical composition for the treatment of gout according to claim 1, wherein: the external medicine composition for treating gout comprises the following raw material components in parts by weight: 5-40 parts of lily, 10-40 parts of Chinese pulsatilla root, 5-30 parts of divaricate saposhnikovia root, 5-20 parts of angelica dahurica, 10-30 parts of trichosanthes root, 3-10 parts of menthol, 4-20 parts of borneol, 0.5-2 parts of azone, 1-5 parts of 1, 3-butanediol, 1, 2-pentanediol, 0.8-1.2 parts of carbomer, 0.02-0.04 part of diethanolamine, 0.08-0.12 part of dipotassium glycyrrhizinate, 0.5-2 parts of methylparaben, 2.5-3.5 parts of glycerol and 50-80 parts of water.
3. The topical pharmaceutical composition for the treatment of gout according to claim 1, wherein: the external medicine composition for treating gout comprises the following raw material components in parts by weight: 35 parts of lily, 25 parts of Chinese pulsatilla root, 10 parts of divaricate saposhnikovia root, 10 parts of angelica dahurica, 13 parts of trichosanthes root, 3 parts of menthol, 4 parts of borneol, 1 part of azone, 4 parts of 1, 3-butanediol, 2 parts of 1, 2-pentanediol, 1 part of carbomer, 0.03 part of diethanolamine, 0.1 part of dipotassium glycyrrhizinate, 1.25 parts of methyl hydroxybenzoate, 3 parts of glycerol and 70 parts of water.
4. The method for preparing a pharmaceutical composition for external use for treating gout according to any one of claims 1 to 3, wherein: the preparation method of the external pharmaceutical composition for treating gout comprises the following steps:
s1, mixing lily and Chinese pulsatilla root to obtain a mixture A, and extracting the mixture A with water to obtain an extracting solution A for later use;
s2, preparing a mixture B from the divaricate saposhnikovia root, the dahurian angelica root and the Mongolian snakegourd root, and extracting the mixture B with water to obtain an extracting solution B for later use;
s3, mixing menthol and borneol, and grinding the mixture into semi-liquid state to obtain a mixture C for later use;
s4, mixing the extracting solution A and the extracting solution B, and concentrating to obtain a concentrated solution;
s5, adding the mixture C, glycerol, half of 1, 3-butanediol, half of 1, 2-pentanediol, glycerol and the balance of water into the concentrated solution, uniformly mixing, heating, emulsifying, cooling, adding azone, half of 1, 3-butanediol, half of 1, 2-pentanediol, dipotassium glycyrrhizinate and methyl paraben, uniformly mixing, adding triethanolamine to adjust the pH value, and preparing a mixture D;
s6, filling or pasting the mixture D to obtain the external medicine composition for treating gout;
in step S1, the weight ratio of the mixture a to water is 1: 6; in step S2, the weight ratio of the mixture B to water is 1: 5.
5. the method for preparing a pharmaceutical composition for external use for treating gout according to claim 4, wherein: in step S1, the extraction is performed at 100 ℃ for 2 times, each time for 5 hours.
6. The method for preparing a pharmaceutical composition for external use for treating gout according to claim 4, wherein: in step S2, the extraction is performed 2 times at 100 ℃ for 2 hours each time.
7. The method for preparing a pharmaceutical composition for external use for treating gout according to claim 4, wherein: in step S4, the concentration is carried out until the density is 1.1g/cm3。
8. The method for preparing a pharmaceutical composition for external use for treating gout according to claim 4, wherein: in step S5, the PH is adjusted to 6.6-7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011084696.2A CN112043788A (en) | 2020-10-12 | 2020-10-12 | A topical pharmaceutical composition for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011084696.2A CN112043788A (en) | 2020-10-12 | 2020-10-12 | A topical pharmaceutical composition for treating gout and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112043788A true CN112043788A (en) | 2020-12-08 |
Family
ID=73605641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011084696.2A Pending CN112043788A (en) | 2020-10-12 | 2020-10-12 | A topical pharmaceutical composition for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112043788A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190099465A1 (en) * | 2016-04-08 | 2019-04-04 | Korea Institute Of Oriental Medicine | Composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising extract of alpinia oxyphylla as effective ingredient |
-
2020
- 2020-10-12 CN CN202011084696.2A patent/CN112043788A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190099465A1 (en) * | 2016-04-08 | 2019-04-04 | Korea Institute Of Oriental Medicine | Composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising extract of alpinia oxyphylla as effective ingredient |
Non-Patent Citations (4)
| Title |
|---|
| 吉林舒润药业有限公司: "《https://www.jinchutou.com/p-132350732.html 》", 14 May 2020 * |
| 周德生: "《中医偏方全书（珍藏本）豪华精装版》", 31 August 2018, 湖南科学技术出版社 * |
| 邓强等: "《中西医结合脊柱疾病治疗学》", 31 July 2007, 甘肃文化出版社 * |
| 顾煜等: "隔百合冰片饼灸治疗痛风性关节炎临床观察", 《上海中医药杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022022339A (en) | Crude-drug-containing pharmaceutical composition | |
| Diniz et al. | Centella asiatica and its metabolite asiatic acid: wound healing effects and therapeutic potential | |
| CN102793785A (en) | Chinese rhubarb-baical skullcap root-amur corktree bark itching-relieving liniment and preparation method thereof | |
| CN112043788A (en) | A topical pharmaceutical composition for treating gout and preparation method thereof | |
| CN101433544B (en) | External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use | |
| DhAnDe et al. | Anti-inflammatory and analgesic activities of topical formulations of Pterocarpus santalinus powder in rat model of chronic inflammation | |
| CN103536450B (en) | Anti-acne external product and effective ingredient preparation method thereof | |
| CN104147584A (en) | Medicine for treating beriberi and manufacturing method thereof | |
| Hanafiah et al. | Formulation and evaluation of binahong leaves extract gel on wound healing of the palatal mucosa | |
| Gopalakrishnan | Insignificant antifungal activity of plant extracts on Malassezia furfur | |
| TWI663982B (en) | Use of hand-fragrant extract for preparing antimicrobial composition | |
| CN104758405A (en) | Preparation method of acne-removing ointment | |
| CN105596600A (en) | Patch for treating radiodermatitis and preparing method thereof | |
| CN108030862A (en) | A kind of oral cavity Chinese medicine film and preparation method thereof | |
| CN113413422A (en) | A topical pharmaceutical composition with antipruritic, antibacterial and antiinflammatory effects, and its preparation method | |
| Roberts et al. | A case study in the use of capsaicin in the treatment of neuropathic chest wall pain and post-thoracotomy intercostal neuralgia | |
| CN102973630B (en) | Traditional Chinese medicine combination and preparation method thereof | |
| CN102415953A (en) | Deodorizing medicinal cosmetic and preparation method thereof | |
| Ibezim et al. | WOUND HEALING PROPERTIES OF OINTMENT FORMULATIONS OF OCIMUM GRATISSIMUM CRUDE N-HEXANE BARK EXTRACTS USING THE EXCISION WOUND MODEL. | |
| CN101416976B (en) | External medicine composition preparation with anti-inflammation detumescence pain-easing function | |
| CN101708152A (en) | Medicated toothpaste | |
| Meher | Comparative wound healing activity of plant Ichnocarpus frutescens (L.) Wt Aiton | |
| Afen Eneji et al. | Anti-inflammatory and Analgesic Effects of Aqueous and Methanol Leaf Extracts of Chrysophyllum Albidum in Male Wistar Rats with Acetic Acid Induced Inflammation and Pain | |
| Rahman et al. | Analgesic activity of methanol extract and its fractions of Streblus asper (Lour.) roots | |
| CN105708842A (en) | Pharmaceutical composition for external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201208 |
|
| RJ01 | Rejection of invention patent application after publication |